The Efficacy and Safety of Roxadustat for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis

The Efficacy and Safety of Roxadustat for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis

Background: Chronic kidney disease (CKD) is a global public health problem, and anemia is a common complication in CKD patients. Roxadustat (FG-4592) is an oral hypoxia-inducible factor (HIF) stabilizer. Roxadustat has been shown in studies to keep up with and increase hemoglobin better than placebo...

Full description

Bibliographic Details
Main Authors:	Lijun Wang, Heng Yin, Liling Yang, Fenglian Zhang, Song Wang, Dan Liao
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-04-01
Series:	Frontiers in Pharmacology
Subjects:	Anemia chronic kidney disease meta-analysis roxadustat CKD FG-4592
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2022.779694/full

Similar Items

Roxadustat (FG-4592) abated lipopolysaccharides-induced depressive-like symptoms via PI3K signaling
by: Axiang Li, et al.
Published: (2023-03-01)

The efficacy and safety of roxadustat for anemia in patients with dialysis-dependent chronic kidney disease: a systematic review and meta-analysis
by: Qiaoqiao Zhou, et al.
Published: (2023-12-01)

Safety and Efficacy of Roxadustat for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis and Trial Sequential Analysis
by: Chao Liu, et al.
Published: (2021-08-01)

Efficacy and safety of roxadustat for the treatment of anemia in non-dialysis chronic kidney disease patients: A systematic review and meta-analysis of randomized double-blind controlled clinical trials
by: Ting Chen, et al.
Published: (2022-11-01)

Efficacy and Safety of Roxadustat in Chinese Hemodialysis Patients: A Systematic Review and Meta-Analysis
by: Qichen Liang, et al.
Published: (2023-03-01)

Iron Parameters in Patients Treated with Roxadustat for Anemia of Chronic Kidney Disease
by: Tomas Ganz, et al.
Published: (2023-06-01)

Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against renal ischemia/reperfusion injury by inhibiting inflammation
by: A-Feng Miao, et al.
Published: (2021-01-01)

Impact of C-reactive protein on the effect of Roxadustat for the treatment of anemia in chronic kidney disease: a systematic review of randomized controlled trials
by: Xiaoyu Luo, et al.
Published: (2024-02-01)

Risk of infection in roxadustat treatment for anemia in patients with chronic kidney disease: A systematic review with meta-analysis and trial sequential analysis
by: Shan Chong, et al.
Published: (2022-09-01)

Roxadustat on Renal Anemia with Macroinflammation: A Retrospective Cohort Study
by: Yan Tu, et al.
Published: (2024-03-01)

Influencing factors of clinical efficacy of roxadustat among hemodialysis patients
by: Wenhui Wu, et al.
Published: (2024-12-01)

Roxadustat in treating anemia in dialysis patients (ROAD): protocol and rationale of a multicenter prospective observational cohort study
by: Yaling Zhang, et al.
Published: (2021-01-01)

Roxadustat: Not just for anemia
by: Xiaoyu Zhu, et al.
Published: (2022-08-01)

Roxadustat treatment for anemia in peritoneal dialysis patients: A randomized controlled trial
by: Yan-Pei Hou, et al.
Published: (2022-02-01)

Cardiovascular and renal safety outcomes of hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat for anemia patients with chronic kidney disease: a systematic review and meta-analysis
by: Lei Tian, et al.
Published: (2024-12-01)

Roxadustat for Patients with Posttransplant Anemia: A Narrative Review
by: Xiaoxiao Tang, et al.
Published: (2023-11-01)

Effects of roxadustat on anemia, iron metabolism, and lipid metabolism in patients with non-dialysis chronic kidney disease
by: Keiji Hirai, et al.
Published: (2023-02-01)

Research progress on roxadustat treatment for renal anemia
by: HU Bao-li, HU Bin
Published: (2022-09-01)

Efficacy of Roxadustat on anemia and residual renal function in patients new to peritoneal dialysis
by: Tong Wu, et al.
Published: (2022-12-01)

The role of roxadustat in chronic kidney disease patients complicated with anemia
by: Jie Liu, et al.
Published: (2023-03-01)

Activation of Intestinal HIF2α Ameliorates Iron‐Refractory Anemia
by: Yingying Yu, et al.
Published: (2024-03-01)

Thyroid function analysis after roxadustat or erythropoietin treatment in patients with renal anemia: a cohort study
by: Xiaomeng Zheng, et al.
Published: (2023-12-01)

Roxadustat regulates iron metabolism in dialysis-dependent and non-dialysis-dependent chronic kidney disease patients: A meta-analysis
by: Yan-Pei Hou, et al.
Published: (2022-11-01)

Roxadustat (FG-4592) Facilitates Recovery From Renal Damage by Ameliorating Mitochondrial Dysfunction Induced by Folic Acid
by: Xue Li, et al.
Published: (2022-02-01)

Cardiovascular Protective Effects of Oral Hypoxia Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat in the Treatment of Type 4 Cardiorenal-Anemia Syndrome: Protocol of a Randomized Controlled Trial
by: Yumin Wen, et al.
Published: (2022-04-01)

Effects of Roxadustat on the Anemia and Iron Metabolism of Patients Undergoing Peritoneal Dialysis
by: Keiji Hirai, et al.
Published: (2021-07-01)

Effectiveness and Safety of Roxadustat for Renal Anemia in Dialysis-dependent Chronic Kidney Disease: a Meta-analysis
by: LI Jiaqing, YANG Qing, YUAN Dunlu, HUANG Jingjing, CHANG Qing, NIE Jingwen, ZHOU Zhu, LI Qing
Published: (2023-02-01)

FG-4592 relieves diabetic kidney disease severity by influencing metabolic profiles via gut microbiota reconstruction in both human and mouse models
by: Yumin Jiang, et al.
Published: (2023-08-01)

Roxadustat: Do we know all the answers?
by: Qiu-Yu Li, et al.
Published: (2023-05-01)

Suppression of thyrotropin secretion during roxadustat treatment for renal anemia in a patient undergoing hemodialysis
by: Mitsuru Ichii, et al.
Published: (2021-03-01)

Clinical Potential of Hypoxia Inducible Factors Prolyl Hydroxylase Inhibitors in Treating Nonanemic Diseases
by: Mengqiu Miao, et al.
Published: (2022-02-01)

Prolyl hydroxylase inhibitor FG-4592 alleviates neuroinflammation via HIF-1/BNIP3 signaling in microglia
by: Qianqian Ruan, et al.
Published: (2024-04-01)

A Novel Choice to Correct Inflammation-Induced Anemia in CKD: Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat
by: Zhipeng Yan, et al.
Published: (2020-08-01)

FG-4592 protects the intestine from irradiation-induced injury by targeting the TLR4 signaling pathway
by: Zhenlan Feng, et al.
Published: (2022-06-01)

Inhibition of OGFOD1 by FG4592 confers neuroprotection by activating unfolded protein response and autophagy after ischemic stroke
by: Jian Xie, et al.
Published: (2024-03-01)

Roxadustat reduced the risk of perioperative complication arising from the treatment of cardiac paraganglioma: A case report
by: Dong Wang, et al.
Published: (2023-09-01)

Roxadustat Attenuates the Disruption of Epithelial Tight Junction in Caco2 Cells and a Rat Model of CKD Through MicroRNA-223
by: Ning Qu, et al.
Published: (2022-04-01)

Therapeutic Potential of a Prolyl Hydroxylase Inhibitor FG-4592 for Parkinson’s Diseases in Vitro and in Vivo: Regulation of Redox Biology and Mitochondrial Function
by: Xuan Li, et al.
Published: (2018-04-01)

A Pharmacodynamic Evaluation of the Protective Effects of Roxadustat Against Hypoxic Injury at High Altitude
by: Guo Q, et al.
Published: (2023-01-01)

Effects of Roxadustat on Erythropoietin Production in the Rat Body
by: Yukiko Yasuoka, et al.
Published: (2022-02-01)